OTC: ACUT

Accustem Sciences Inc.

CIK 0001850767 · SIC 2834 · Pharmaceutical Preparations

Micro by assets Assets $83K as of Nov 21, 2026

Every 8-K is open in full. Other 10-Ks and 10-Qs show a 3-bullet preview. A free account reads 3 more full reports a month. Generating a report requires a verified account.

Sign up free

Want to see a complete report first? Today's free report (JEF 10-Q) is open in full — no account needed.

10-Q Filed Nov 20, 2026 · Period ending Sep 30, 2026

Summary not yet generated.

10-Q Filed Aug 14, 2026 · Period ending Jun 30, 2026

Summary not yet generated.

Partner

Trade ACUT commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

10-K Filed Apr 14, 2026 · Period ending Dec 31, 2025

Summary not yet generated.

8-K Filed Nov 26, 2025 · Period ending Nov 26, 2025

Summary not yet generated.

10-K Filed Apr 3, 2025 · Period ending Dec 31, 2024

Summary not yet generated.

8-K Filed Dec 30, 2024 · Period ending Jun 17, 2024

Summary not yet generated.

8-K Filed Apr 10, 2024 · Period ending Apr 4, 2024

Summary not yet generated.

10-K/A Filed Apr 28, 2023 · Period ending Dec 31, 2022

Summary not yet generated.

S-1/A Filed Jan 19, 2023

Summary not yet generated.

S-1 Filed Nov 17, 2022

Summary not yet generated.

Latest financial statements

From 10-Q filed Nov 20, 2026 (period ending Sep 30, 2026). As printed on the EDGAR/iXBRL face — not generated by the model.

As filed

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited)

Description Three months ended September 30 2026 Three months ended September 30 2025 Nine months ended September 30 2026 Nine months ended September 30 2025
OPERATING EXPENSES
Research and development expenses 14,359 72,720 79,196 161,270
Acquired in-process research and development expense 1,500,000 - 1,500,000 -
General and administrative expenses 355,536 327,177 1,029,155 1,080,438
Total operating expenses 1,869,895 399,897 2,608,351 1,241,708
LOSS FROM OPERATIONS (1,869,895) (399,897) (2,608,351) (1,241,708)
Income tax benefit (expense)
NET LOSS (1,869,895) (399,897) (2,608,351) (1,241,708)
Net loss per share attributable to common stockholders, basic and diluted (0.12) (0.02) (0.16) (0.08)
Weighted average common shares outstanding used in computing net loss per share attributable to common stockholders, basic and diluted 16,072,267 16,072,267 16,072,267 14,950,840

Condensed Consolidated Balance Sheets (Unaudited)

Description September 30, 2026 December 31, 2025
ASSETS
Current Assets
Cash 15,303 13,929
Prepaid expenses 67,898 35,517
Total Current Assets 83,201 49,446
Equipment, net — —
Other non-current assets — 1,500,000
TOTAL ASSETS 83,201 1,549,446
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current Liabilities
Accounts payable 640,022 703,812
Related party payable 5,363,673 4,222,838
Accrued expenses 17,527 1,875
Note Payable 42,108 22,546
Total Current Liabilities 6,063,330 4,951,071
TOTAL LIABILITIES 6,063,330 4,951,071
Shareholders’ Equity
Preferred stock $.001 par value; 10,000,000 shares authorized; none issued and outstanding - -
Common stock $.001 par value; 150,000,000 shares authorized; 16,072,267 shares issued and outstanding as of September 30, 2026 and 16,072,267 shares issued and outstanding as of December 31, 2025 16,072 16,072
Additional paid-in capital 6,395,293 6,365,446
Accumulated deficit (12,391,494) (9,783,143)
TOTAL SHAREHOLDERS’ EQUITY (5,980,129) (3,401,625)
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY 83,201 1,549,446

Condensed Consolidated Statements of Cash Flows (Unaudited)

Description Nine months ended September 30 2026 Nine months ended September 30 2025
Operating Activities
Net loss (2,608,351) (1,241,708)
Adjustments to reconcile net loss to net cash used in (provided by) operating activities
Depreciation - 418
Share-based compensation 29,847 65,022
Expenses settled in stock - 79,000
Acquired in-process research and development expense 1,500,000 -
Change in operating assets and liabilities:
Prepaid expenses 56,623 80,981
Accounts payable (63,790) 118,576
Related party payable 205,835 39,244
Accrued expenses 15,652 (14,279)
Net cash used in (provided by) operating activities (864,184) (872,746)
Financing Activities
Advances from related party 935,000 957,000
Payments on note payable (69,442) (74,909)
Net cash used in (provided by) financing activities 865,558 882,091
(Decrease)/Increase in cash 1,374 9,345
Cash, beginning of period 13,929 5,046
Cash, end of period 15,303 14,391
Supplemental disclosure of noncash investing and financing activities
Issuance of Note Payable for payment of prepaid expense 87,409 92,597
Cash paid for interest 1,594 1,854
Shares issued pending non-cash transaction - 1,500,000

Amounts as printed on the EDGAR/iXBRL face. Labels, columns, and figures are the filing face, not a GAAP stencil. Interactive statements & notes on EDGAR ↗